


# TATTOOS\* Mini-Symposium



# Topics & Invited Speakers

**Background of the symposium:** As part of the strategic planning period 2025-2028 of the ETH Board for the ETH Domain, the Paul Scherrer Institute proposes a large research infrastructure project. The project entails the installation of a new beam line at the High Intensity Proton Accelerator (HIPA) facility at the PSI, with its world-record intensity proton beam, to produce innovative radionuclides for medical purposes particularly for targeted alpha-particle therapy of cancer at the quality and quantity necessary for clinical application. *TATTOOS* should also comprise laboratories for the aseptic production of novel radionuclides and radiopharmaceuticals that will be made available to hospitals and enable world-first clinical studies.

At this Mini-Symposium world-renowned key-opinion leaders in physics and medicine will highlight the importance of radiolabelled drugs for the diagnosis and treatment of cancer in the coming decades.

**If you are interested to join the webinar please register (for free) at** <https://indico.psi.ch/event/11148/registrations/1461/>

The Mini-Symposium is hosted by the Center for Radiopharmaceutical Sciences at the Paul Scherrer Institute.



Prof R. Baum  
CURANOSTICUM  
Germany



Prof. M. Hofman  
Peter MacCallum Cancer Centre  
Australia



Prof. U. Köster  
Institut Laue-Langevin  
France



Prof. G. Thalmann  
Inselspital Bern  
Switzerland



Prof. D. Wild  
University Hospital Basel  
Switzerland

# Event Programme

	Moderated by M. van Daalen	
C. Rüegg (Director of PSI)	<b>Opening Remarks</b>	08.30
R. Schibli	Chair	08.45
N. van der Meulen	<b><i>TATTOOS – project plans at PSI</i></b>	08.50 (20 + 5 min questions)
Prof. Michael Hofman (Peter MacCallum Cancer Centre, Melbourne, Australia)	<b><i>A new Era of Treating Prostate Cancer: Improving Outcomes with Theranostics</i></b>	09.15 (20 min + 5 min questions)
Prof. Richard Baum (CURANOSTICUM Wiesbaden-Frankfurt, Germany)	<b><i>Experience and perspectives of non-standard radionuclides for theragnostic.</i></b>	09.40 (20 min + 5 min questions)
	<b><i>Short break</i></b>	10.05 min
C. Müller	Chair	10.15
Prof. George Thalmann (Inselspital, Bern, Bern, Switzerland)	<b><i>Theranostics in prostate cancer: the urologists view of unmet needs and hopes</i></b>	10.40 (20 min + 5 min questions)
Prof. Damian Wild (University Hospital Basel, Basel Switzerland)	<b><i>Theranostics in Neuroendocrine Neoplasia (NEN) – new Treatment Options</i></b>	11.05 (20 min + 5 min questions)
Dr. Ulli Köster (Institut Laue-Langevin, Grenoble, France)	<b><i>Production of emerging radionuclides</i></b>	11.30 (20 + 5 min question)s
	<b><i>Short break</i></b>	11.55
R. Schibli	<b>Round Table Discussion (Q&amp;A Session)</b> with: - Directorate, invited Speakers, representative of LRC, representative of CRS, invited Medical Doctors, representatives of industry	12.05 (45 min)
	Break	
	Closing remarks	13.00